Literature DB >> 29545346

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.

Ibrahim Aldoss1, Dongyun Yang2, Ahmed Aribi1, Haris Ali1, Karamjeet Sandhu1, Monzr M Al Malki1, Matthew Mei1, Amandeep Salhotra1, Samer Khaled1, Ryotaro Nakamura1, David Snyder1, Margaret O'Donnell1, Anthony S Stein1, Stephen J Forman1, Guido Marcucci1, Vinod Pullarkat3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29545346      PMCID： PMC6119155          DOI： 10.3324/haematol.2018.188094

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

Review 1.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

2.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellström-Lindberg; Valeria Santini; Norbert Gattermann; Ulrich Germing; Guillermo Sanz; Alan F List; Steven Gore; John F Seymour; Hervé Dombret; Jay Backstrom; Linda Zimmerman; David McKenzie; C L Beach; Lewis R Silverman
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

3.  Azacitidine for the treatment of relapsed and refractory AML in older patients.

Authors:  Raphael Itzykson; Sylvain Thépot; Céline Berthon; Jacques Delaunay; Didier Bouscary; Thomas Cluzeau; Pascal Turlure; Thomas Prébet; Caroline Dartigeas; Jean-Pierre Marolleau; Christian Recher; Isabelle Plantier; Aspasia Stamatoullas; Alain Devidas; Anne-Laure Taksin; Romain Guièze; Denis Caillot; Norbert Vey; Lionel Adès; Norbert Ifrah; Hervé Dombret; Pierre Fenaux; Claude Gardin
Journal:  Leuk Res       Date:  2014-11-24       Impact factor: 3.156

4.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

Authors:  Hervé Dombret; John F Seymour; Aleksandra Butrym; Agnieszka Wierzbowska; Dominik Selleslag; Jun Ho Jang; Rajat Kumar; James Cavenagh; Andre C Schuh; Anna Candoni; Christian Récher; Irwindeep Sandhu; Teresa Bernal del Castillo; Haifa Kathrin Al-Ali; Giovanni Martinelli; Jose Falantes; Richard Noppeney; Richard M Stone; Mark D Minden; Heidi McIntyre; Steve Songer; Lela M Lucy; C L Beach; Hartmut Döhner
Journal:  Blood       Date:  2015-05-18       Impact factor: 22.113

5.  Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

Authors:  Marina Konopleva; Daniel A Pollyea; Jalaja Potluri; Brenda Chyla; Leah Hogdal; Todd Busman; Evelyn McKeegan; Ahmed Hamed Salem; Ming Zhu; Justin L Ricker; William Blum; Courtney D DiNardo; Tapan Kadia; Martin Dunbar; Rachel Kirby; Nancy Falotico; Joel Leverson; Rod Humerickhouse; Mack Mabry; Richard Stone; Hagop Kantarjian; Anthony Letai
Journal:  Cancer Discov       Date:  2016-08-12       Impact factor: 39.397

6.  BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.

Authors:  Eleni D Lagadinou; Alexander Sach; Kevin Callahan; Randall M Rossi; Sarah J Neering; Mohammad Minhajuddin; John M Ashton; Shanshan Pei; Valerie Grose; Kristen M O'Dwyer; Jane L Liesveld; Paul S Brookes; Michael W Becker; Craig T Jordan
Journal:  Cell Stem Cell       Date:  2013-01-17       Impact factor: 24.633

7.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Authors:  Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

8.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

9.  Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.

Authors:  Shaji Kumar; Jonathan L Kaufman; Cristina Gasparetto; Joseph Mikhael; Ravi Vij; Brigitte Pegourie; Lofti Benboubker; Thierry Facon; Martine Amiot; Philippe Moreau; Elizabeth A Punnoose; Stefanie Alzate; Martin Dunbar; Tu Xu; Suresh K Agarwal; Sari Heitner Enschede; Joel D Leverson; Jeremy A Ross; Paulo C Maciag; Maria Verdugo; Cyrille Touzeau
Journal:  Blood       Date:  2017-10-10       Impact factor: 22.113

10.  BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.

Authors:  J M Bogenberger; S M Kornblau; W E Pierceall; R Lena; D Chow; C-X Shi; J Mantei; G Ahmann; I M Gonzales; A Choudhary; R Valdez; J Camoriano; V Fauble; R E Tiedemann; Y H Qiu; K R Coombes; M Cardone; E Braggio; H Yin; D O Azorsa; R A Mesa; A K Stewart; R Tibes
Journal:  Leukemia       Date:  2014-01-23       Impact factor: 11.528
  10 in total
  63 in total

Review 1.  New Treatment Options for Acute Myeloid Leukemia in 2019.

Authors:  Marco Cerrano; Raphael Itzykson
Journal:  Curr Oncol Rep       Date:  2019-02-04       Impact factor: 5.075

2.  Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia.

Authors:  Ibrahim Aldoss; Jianying Zhang; Raju Pillai; Geoffrey Shouse; James F Sanchez; Matthew Mei; Ryotaro Nakamura; Anthony S Stein; Stephen J Forman; Guido Marcucci; Vinod Pullarkat
Journal:  Br J Haematol       Date:  2019-08-22       Impact factor: 6.998

Review 3.  Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia.

Authors:  Longzhen Cui; Yan Liu; Yifan Pang; Tingting Qian; Liang Quan; Zhiheng Cheng; Yifeng Dai; Xu Ye; Ying Pang; Jinlong Shi; Xiaoyan Ke; Depei Wu; Lin Fu
Journal:  Cancer Gene Ther       Date:  2019-07-11       Impact factor: 5.987

Review 4.  Venetoclax-based therapies for acute myeloid leukemia.

Authors:  Veronica A Guerra; Courtney DiNardo; Marina Konopleva
Journal:  Best Pract Res Clin Haematol       Date:  2019-05-24       Impact factor: 3.020

5.  Ceramide Analogue SACLAC Modulates Sphingolipid Levels and MCL-1 Splicing to Induce Apoptosis in Acute Myeloid Leukemia.

Authors:  Jennifer M Pearson; Su-Fern Tan; Arati Sharma; Charyguly Annageldiyev; Todd E Fox; Jose Luis Abad; Gemma Fabrias; Dhimant Desai; Shantu Amin; Hong-Gang Wang; Myles C Cabot; David F Claxton; Mark Kester; David J Feith; Thomas P Loughran
Journal:  Mol Cancer Res       Date:  2019-11-19       Impact factor: 5.852

6.  Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.

Authors:  Maximilian Stahl; Kamal Menghrajani; Andriy Derkach; Alexander Chan; Wenbin Xiao; Jacob Glass; Amber C King; Anthony F Daniyan; Christopher Famulare; Bernadette M Cuello; Troy Z Horvat; Omar Abdel-Wahab; Ross L Levine; Aaron D Viny; Eytan M Stein; Sheng F Cai; Mikhail Roshal; Martin S Tallman; Aaron D Goldberg
Journal:  Blood Adv       Date:  2021-03-09

Review 7.  Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy.

Authors:  Jenna L Carter; Katie Hege; Jay Yang; Hasini A Kalpage; Yongwei Su; Holly Edwards; Maik Hüttemann; Jeffrey W Taub; Yubin Ge
Journal:  Signal Transduct Target Ther       Date:  2020-12-18

8.  Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents.

Authors:  Ibrahim Aldoss; Sanjeet Dadwal; Jianying Zhang; Bernard Tegtmeier; Matthew Mei; Shukaib Arslan; Monzr M Al Malki; Amandeep Salhotra; Haris Ali; Ahmed Aribi; Karamjeet Sandhu; Samer Khaled; David Snyder; Ryotaro Nakamura; Anthony S Stein; Stephen J Forman; Guido Marcucci; Vinod Pullarkat
Journal:  Blood Adv       Date:  2019-12-10

Review 9.  Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs.

Authors:  Lucia Masarova; Courtney D DiNardo; Prithviraj Bose; Naveen Pemmaraju; Naval G Daver; Tapan M Kadia; Helen T Chifotides; Lingsha Zhou; Gautam Borthakur; Zeev Estrov; Marina Konopleva; Srdan Verstovsek
Journal:  Blood Adv       Date:  2021-04-27

10.  Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.

Authors:  Seth E Karol; Thomas B Alexander; Amit Budhraja; Stanley B Pounds; Kristin Canavera; Lei Wang; Joshua Wolf; Jeffery M Klco; Paul E Mead; Soumyasri Das Gupta; Su Y Kim; Ahmed Hamed Salem; Tammy Palenski; Norman J Lacayo; Ching-Hon Pui; Joseph T Opferman; Jeffrey E Rubnitz
Journal:  Lancet Oncol       Date:  2020-03-11       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.